Eli Lilly Stock

2023 - 11 - 8

eli lilly eli lilly

Post cover
Image courtesy of "The Wall Street Journal"

Stock Market Today: S&P 500 Eyes 9-Day Winning Streak; Disney ... (The Wall Street Journal)

One of this year's hottest stocks is on pace for its worst day of the year. Eli Lilly shares are down nearly 5% on Thursday morning.

Post cover
Image courtesy of "Motley Fool"

Why Eli Lilly Stock Is Slumping Today (Motley Fool)

Shares of Eli Lilly and Company (LLY -4.28%) were slumping on Thursday, falling 5.4% lower as of 10:48 a.m. ET. Was there bad news for the big drugmaker?

Post cover
Image courtesy of "Barron's"

Eli Lilly Stock Jumps on Obesity Drug's FDA Approval (Barron's)

Eli Lilly says the list price of its obesity drug, Zepbound, is roughly 20% lower than the list price of Novo Nordisk's Wegovy.

Post cover
Image courtesy of "Investor's Business Daily"

Here's How Lilly Plans To Unseat Novo As The Weight-Loss Drugs ... (Investor's Business Daily)

The FDA approved a highly anticipated weight-loss drug from Eli Lilly on Wednesday. Eli Lilly stock popped on the approval news.

Post cover
Image courtesy of "Bloomberg"

FDA Approves Lilly's Zepbound. A Weight Loss Drug Similar to ... (Bloomberg)

Eli Lilly & Co. won US approval for its diabetes drug to treat obesity, unlocking blockbuster sales potential and sparking a battle for dominance of a ...

Post cover
Image courtesy of "The Washington Post"

FDA approves new obesity drug from Eli Lilly named Zepbound (The Washington Post)

The Food and Drug Administration on Wednesday approved Eli Lilly's diabetes drug for treating obesity, opening the door for widespread insurance coverage ...

Post cover
Image courtesy of "Investors | Eli Lilly and Company"

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight ... (Investors | Eli Lilly and Company)

Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose. Zepbound is the first and only approved treatment activating two ...

Explore the last week